Cboe's KPI binary options proposal splits prediction market regulators

Kalshi's comment letter to the SEC landed on August 5, three weeks before the agency's public comment deadline closed. The argument was precise: the CFTC and SEC had jointly asked the public, just weeks earlier, to help them figure out what these products actually are. Approving Cboe's binary options proposal while that question remained open would be, in Kalshi's framing, premature. The word choice was deliberate. Kalshi did not say the products were illegal. It said nobody had decided yet.

The products in question are binary options that Cboe wants to list on company-specific key performance indicators — revenue, earnings, metrics tied to a named stock issuer. The economic exposure is recognizable: a trader bets on whether a number comes in above or below a threshold, and the contract pays accordingly. What is not settled is whether that makes the instrument a swap, a security-based swap, or a securities option. Each classification routes through a different regulator with different rules. Cboe filed with the SEC, framing the products as binary options rather than event contracts. That framing was not accidental. The SEC pathway is distinct from the CFTC pathway Kalshi built its business through, and the two agencies have not yet aligned on where the boundary sits.

The jurisdictional ambiguity here is not theoretical. When two regulators simultaneously issue a joint request asking the public to clarify a definitional question, and a third party seeks approval of a product that sits directly inside that question, the sequencing matters. Kalshi's position is that approval should follow classification, not precede it. That is a reasonable structural argument. It is also in Kalshi's commercial interest. Both things can be true.

I have seen this pattern before in liquidity market design: a well-resourced incumbent files for approval in an adjacent regulatory lane, and the existing operator objects on procedural grounds that also happen to protect its position. The procedural argument is usually correct. The motive usually coexists. What matters is whether the regulators treat the procedural argument on its merits.

Here is where the consensus read misses something. The commentary on Cboe's filing has largely treated this as a competitive story: Kalshi defending turf, Cboe entering a hot market. The more consequential question is what happens if the SEC approves Cboe's products before the joint CFTC-SEC process produces a classification framework. That outcome would create two live regulatory regimes for economically equivalent instruments, one supervised by the CFTC through Kalshi's designated contract market structure, one supervised by the SEC through Cboe's exchange framework. Market participants would have the same exposure priced under different rules. Arbitrage pressure would follow immediately. The agencies would then face a coordination problem they have already signaled they do not know how to solve.